Newsroom
Contact us
FAQ
Íslenska
  • Company
  • For investors
  • Biosimilars
  • Corporate Sustainability
  • Careers
  • About Us
  • Media Center
  • Careers
  • Newsroom
  • Contact us
  • Terms of Use
  • Privacy Policy
  • Cookie Policy

Alvotech 2025. All rights reserved.

Company Announcement
29 November 2023

Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®

The study, assessing pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi® (golimumab) in healthy adult subjects, met its primary endpoint Alvotech (NASDAQ: ALVO), a global biotech...
Company Announcement
28 November 2023

Alvotech Reports Financial Results for First Nine Months of 2023 and Provides Business Update

Product revenue for the nine months of 2023 increased to $29.8 million, compared to $11.1 million for the same period in 2022Marketing authorization was received for AVT04 in Canada and Japan, the...
Company Announcement
21 November 2023

Alvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Host Business Update Conference Call on November 29, 2023, at 8:00 am ET

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results...
Company Announcement
15 November 2023

Alvotech Accepts Offer to Sell its Subsidiary in Hannover, Germany

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it has accepted the offer of a subsidiary of Light Curve Capital Holdings Pte. Ltd for all shares of Alvotech's subsidiary, Alvotech
Company Announcement
14 November 2023

Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki (AVT04), the First Biosimilar of Stelara® (ustekinumab)

JamtekiTM is the second biosimilar developed under this partnership that receives marketing authorization in Canada. Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development...
Company Announcement
10 November 2023

STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara

CHMP positive opinion in the European Economic Area for first biosimilar to Stelara, a biologic therapy within gastroenterology, dermatology and rheumatologyPositive CHMP opinion for Uzpruvo...
Company Announcement
07 November 2023

Alvotech to Present at the Jefferies 2023 London Healthcare Conference

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies...
Company Announcement
20 October 2023

Form F-3 Filed With the United States Securities and Exchange Commission

Today Alvotech filed a form F-3 registration statement with the U.S. Securities and Exchange Commission. Attached is the complete document as filed.
Company Announcement
12 October 2023

Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the US Food and Drug...
Company Announcement
05 October 2023

Alvotech and Islandsbanki enter into Market Making Agreement for Shares Trading on Nasdaq Iceland

Alvotech (Nasdaq: ALVO) and Íslandsbanki hf. (“Islandsbanki”) have entered into a market making agreement. According to the market making agreement, Islandsbanki places bids and offers for ALVO shares...
1…1718…32